Accidental Overdoses With GLP-1 Weight Loss Drugs Are Spiking, Especially Among Vulnerable Populations | Research

The takeaway

FDA adverse event data reveals 3,348 accidental overdose reports for GLP-1 drugs, with significantly elevated rates across all drugs in the class, linked to online and compounding pharmacy access barriers.

ROR up to 61.12×
Some GLP-1 drugs showed overdose reporting rates over 61 times higher than expected, with all five drugs in the class showing significant signals

What the researchers found

Accidental overdoses with GLP-1 receptor agonists are being reported at disproportionately high rates to the FDA. Across 3,348 reports from 2003 to early 2024, every GLP-1 drug in the class showed significantly elevated reporting odds ratios for accidental overdose:

- ROR range: 2.64 to 61.12 (all statistically significant, p < 0.008)

- Affected drugs: semaglutide, dulaglutide, exenatide, liraglutide, and tirzepatide

The authors link this to patients accessing GLP-1 drugs through online and compounding pharmacies due to cost and availability barriers, with the greatest risk falling on racial, ethnic, and socioeconomically disadvantaged populations.

Why it matters

GLP-1 drugs have become the most sought-after medications in the world, but shortages and costs exceeding $1,000/month are pushing patients toward online pharmacies and compounding services where dosing errors are more likely. This study quantifies the consequence: a significant spike in accidental overdoses across the entire GLP-1 class. The equity dimension is critical — the people most likely to be harmed are those with the least access to FDA-approved products and proper medical supervision.

The numbers in context

3,348 accidental overdose reports · ROR range 2.64–61.12 · all p < 0.008 · 5 GLP-1 drugs affected · Q4 2003 to Q1 2024 · compared to niacin baseline

How the study worked

Retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS). Researchers retrieved all accidental overdose case reports for GLP-1 RAs from Q4 2003 to Q1 2024 using OpenVigil 2.1. Disproportionality was assessed using reporting odds ratios (ROR) with 95% confidence intervals, with niacin as the comparator.

Who was studied

Individuals who reported accidental overdose with GLP-1 receptor agonists to the FDA FAERS database, 2003–2024

What this study cannot tell us

FAERS is a voluntary reporting system — overdoses may be underreported or overreported depending on public awareness and media coverage. The study cannot prove that online/compounding pharmacy access caused the overdoses — only that the association exists. Selection of niacin as comparator may influence ROR magnitude. Individual case details (severity, outcomes, source of medication) were not analyzed. Reporting bias may have increased as GLP-1 drugs gained media attention.

How to read the evidence

Moderate evidence from a large pharmacovigilance database analysis spanning 20 years. The consistent signal across all five GLP-1 drugs strengthens the finding. However, FAERS data is voluntary, cannot prove causation, and is susceptible to reporting bias — particularly for drugs receiving intense media attention.

When this study was published

Published in 2024 using FAERS data through Q1 2024. This is highly current and directly relevant to the ongoing GLP-1 drug access and safety debate.

The bigger picture

The GLP-1 drug access crisis has created a two-tier system: those with insurance and access get FDA-approved products with proper dosing, while those without are navigating a patchwork of online sellers, telehealth clinics, and compounding pharmacies with less oversight. This study shows that the consequences of that gap are measurable in overdose reports. Combined with recent data on quality problems with compounded GLP-1 drugs, it paints a picture of a public health problem driven by drug pricing and availability — not by the drugs themselves.

Questions still open

How many of the accidental overdoses involved compounded or online-sourced GLP-1 drugs versus FDA-approved products?
What were the clinical outcomes of these overdoses — how many required hospitalization or resulted in serious harm?
Would expanding insurance coverage or reducing GLP-1 drug prices decrease accidental overdose rates?

Common questions

Why are accidental overdoses with GLP-1 drugs increasing?

The study points to patients accessing GLP-1 drugs through online and compounding pharmacies due to high costs and shortages of brand-name products. These alternative sources may have different concentrations, confusing labeling, or lack the dosing guidance that comes with FDA-approved products, increasing the risk of accidentally taking too much.

Who is most at risk for accidental GLP-1 overdose?

The researchers specifically highlight racial, ethnic, and socioeconomically disadvantaged populations — groups that are most likely to face barriers accessing FDA-approved medications and may rely on less regulated online or compounding pharmacy sources. These populations are more likely to encounter dosing confusion and less likely to have access to proper medical supervision.

Read the original research

Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.

Expert opinion on drug safety, 1-6

View on PubMed ↗Publisher’s paper ↗

Citation

McIntyre, Roger S; Kwan, Angela T H. (2024). Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.. Expert opinion on drug safety, 1-6. https://doi.org/10.1080/14740338.2024.2430306